Carlyle to buy Baxter renal unit for $3.8B

Carlyle agreed to buy Baxter's (NYSE) Vantive kidney care business for $3.8 billion.

Why it matters: It likely won't be the last large-scale spinoff as corporations continue to optimize their operations.